Abstract
Denosumab is the first fully human monoclonal antibody that inhibits the formation, function and survival of osteoclasts by blocking the interaction of RANKL with its osteoclastic receptor RANK. Clinical studies have shown that the decreased bone resorption and increased bone mineral density resulting from the use of denosumab 60 mg twice yearly entail significant risk reduction of vertebral, hip and non-vertebral fractures in women with postmenopausal osteoporosis, with an acceptable rate of side effects so far. Denosumab offers a new choice for the treatment of postmenopausal osteoporosis in patients at high risk for fractures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.